LAM Therapeutics (United States)

LAM Therapeutics (United States) is a clinical-stage biopharmaceutical company headquartered in Guilford, Connecticut, focused on developing treatments for pulmonary conditions with high unmet medical need. The company is now publicly associated with the name Orphai Therapeutics, which operates the website orphai-therapeutics.com and describes a pipeline centered on mTOR (mechanistic Target of Rapamycin) dysregulation as a central pathological driver of inflammation, fibrosis, vascular remodeling, and airway remodeling across multiple severe lung diseases. The company's lead investigational asset is LAM 001, a proprietary, once-daily inhaled formulation of sirolimus (also known as rapamycin). LAM-001 is designed to inhibit mTOR-mediated pulmonary dysfunction, with the goal of exerting anti-proliferative, anti-fibrotic, and immunomodulatory effects. The biological rationale is that dampening aberrant mTOR signaling could modify disease progression in pulmonary indications where unchecked cellular growth and tissue remodeling contribute to pathology. LAM Therapeutics is targeting severe pulmonary diseases including pulmonary hypertension (PH), including PH associated with interstitial lung diseases (PH ILD) and sarcoidosis-associated PH (SAPH), as well as bronchiolitis obliterans syndrome (BOS), a progressive and often life-threatening form of chronic lung allograft dysfunction that remains one of the most serious complications of lung transplantation. According to the company, no approved therapies fully address the underlying pathophysiology of these diseases, and no approved therapies exist today for BOS. The company is privately held and operates primarily in the United States. Its corporate identity has evolved to include the Orphai Therapeutics name, which now serves as the public-facing brand for its pulmonary-focused development programs. The company's strategy centers on reformulating an established mTOR inhibitor for inhaled, local delivery to the lung, aiming to address the underlying drivers of disease rather than only managing symptoms.

LAM Therapeutics (United States) is a clinical-stage biopharmaceutical company based in Guilford, Connecticut. The company has focused its development efforts on pulmonary diseases driven by dysregulation of mTOR (mechanistic Target of Rapamycin) signaling, a pathway implicated in inflammation, fibrosis, and vascular and airway remodeling across multiple severe lung conditions. The company's lead program, LAM 001, is a proprietary, investigational, once-daily inhaled formulation of sirolimus (rapamycin). By delivering a known mTOR inhibitor directly to the lung via inhalation, LAM Therapeutics aims to dampen aberrant mTOR-mediated signaling and thereby exert anti-proliferative, anti-fibrotic, and immunomodulatory effects. The company's stated biological rationale is to explore mTOR inhibition across pulmonary indications where unchecked cellular growth and tissue remodeling contribute to disease progression. The company has targeted pulmonary hypertension (PH), including PH associated with interstitial lung diseases (PH ILD) and sarcoidosis-associated PH (SAPH), as well as bronchiolitis obliterans syndrome (BOS), a progressive and often life-threatening form of chronic lung allograft dysfunction that is a serious complication of lung transplantation. According to the company, no approved therapies fully address the underlying pathophysiology of these diseases, and no approved therapies exist today for BOS. At some point in its corporate evolution, the company became publicly associated with the name Orphai Therapeutics, which now operates the website orphai-therapeutics.com and presents the pulmonary-focused pipeline. The company is privately held and headquartered in Guilford, Connecticut, in the United States. Detailed information about its founding year, founders, investors, and financing history is not available in the supplied evidence.

Clinical-stage biopharmaceutical company developing disease-modifying inhaled mTOR inhibitor therapies for severe pulmonary diseases with high unmet medical need.

• LAM 001

  A proprietary, investigational, once-daily inhaled formulation of sirolimus (rapamycin) designed to inhibit mTOR-mediated pulmonary dysfunction, with anti-proliferative, anti-fibrotic, and immunomodulatory effects.

1. 1Pulmonary diseases driven by mTOR dysregulation I Orphai Therapueticsorphai-therapeutics.com
2. 2LAM Therapeutics (United States) - Wikidatawikidata.org